Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome
- 7 October 2011
- journal article
- research article
- Published by Wiley in Psycho‐Oncology
- Vol. 22 (2), 276-289
- https://doi.org/10.1002/pon.2080
Abstract
Objective CDKN2A/p16 mutations confer 76% lifetime risk of melanoma and up to 17% lifetime risk of pancreatic cancer. Our objective was to determine the short- and long-term impact of CDKN2A/p16 genetic counseling and test reporting on psychological distress, cancer worry, and perceived costs and benefits of testing. Methods Prospective changes in anxiety, depression, and cancer worry following CDKN2A/p16 counseling and test reporting were evaluated at multiple assessments over 2 years among 60 adult members of melanoma-prone families; 37 participants completed the 2-year follow-up. Quantitative and qualitative assessments of the costs and benefits of testing were carried out. Outcomes were evaluated among unaffected noncarriers (n = 27), unaffected carriers (n = 15), and affected carriers (n = 18). Results Reported anxiety and depression were low. For carriers and noncarriers, anxiety decreased significantly throughout the 2-year period, whereas depression and melanoma worry showed short-term decreases. Worry about pancreatic cancer was low and decreased significantly. In all groups, test-related distress and uncertainty were low, regret was absent, and positive experiences were high. All participants (>93% at each assessment) reported at least one perceived benefit of genetic testing; only 15.9% listed any negative aspect. Carriers reported increased knowledge about melanoma risk and prevention (78.3%) and increased prevention and screening behaviors for self and family (65.2%). Noncarriers reported increased knowledge (95.2%) and emotional benefits (71.4%). Conclusion Among US participants familiar with their hereditary melanoma risk through prior epidemiological research participation, CDKN2A/p16 genetic testing provides multiple perceived benefits to both carriers and noncarriers without inducing distress in general or worry about melanoma or pancreatic cancer. Copyright © 2011 John Wiley & Sons, Ltd.Keywords
This publication has 29 references indexed in Scilit:
- Disclosing Individual CDKN2A Research Results to Melanoma Survivors: Interest, Impact, and Demands on ResearchersCancer Epidemiology, Biomarkers & Prevention, 2011
- Missing Data Analysis: Making It Work in the Real WorldAnnual Review of Psychology, 2009
- Emotional distress following genetic testing for hereditary breast and ovarian cancer: A meta-analytic review.Health Psychology, 2009
- Genetic testing in familial melanoma: uptake and implicationsPsycho‐Oncology, 2008
- CDKN2A/p16 Genetic Test Reporting Improves Early Detection Intentions and Practices in High-Risk Melanoma FamiliesCancer Epidemiology, Biomarkers & Prevention, 2008
- Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continentsJournal of Medical Genetics, 2006
- Population-Based Analysis of Prognostic Factors and Survival in Familial MelanomaJournal of Clinical Oncology, 2005
- Hereditary melanoma and predictive genetic testing: why not?Psycho‐Oncology, 2005
- Geographical Variation in the Penetrance of CDKN2A Mutations for MelanomaJNCI Journal of the National Cancer Institute, 2002
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983